EP3911354
AAV-miðluð genameðhöndlun til að laga Otoferlin-genið
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
20.1.2020EP published:
19.7.2023EP application number:
20701951.4
EP translation filed:
16.10.2023Grant published:
15.11.2023EPO information:
European Patent Register
Max expiry date:
19.1.2040Expiry date:
19.1.2027Next due date:
31.1.2027
Title in English:
AAV-MEDIATED GENE THERAPY RESTORING THE OTOFERLIN GENELanguage of the patent:
English
Timeline
Today
20.1.2020EP application
19.7.2023EP Publication
16.10.2023Translation submitted
15.11.2023Registration published
19.1.2027Expires
Owner
Name:
Institut PasteurAddress:
25-28, rue du Docteur Roux, 75015 Paris, FR
Name:
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Address:
3, rue Michel-Ange, 75016 Paris, FR
Name:
Institut National de la Santé et de la Recherche Médicale (INSERM)Address:
101 rue Tolbiac, 75013 Paris, FR
Inventor
Name:
SAFIEDDINE, SaaidAddress:
75012 Paris, FR
Name:
PETIT, ChristineAddress:
75012 Paris, FR
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
19305071Date:
18.1.2019Country:
EP
Classification
Categories:
A61K 38/16, A61K 48/00, C07K 14/00, C12N 15/86, A61P 27/16
Annual fees
Number
Paid
Expires
Payer
Number: 5
Paid: 20.12.2023
Expires: 19.1.2025
Payer: Acumass
Number: 6
Paid: 13.1.2025
Expires: 19.1.2026
Payer: G.H. Sigurgeirsson ehf.
Number: 7
Paid: 12.1.2026
Expires: 19.1.2027
Payer: G.H. Sigurgeirsson ehf.